Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2018
Akcea and Ionis announce approval of Tegsedi (inotersen injection) in Canada
4 October 2018 - First and only treatment of its kind for Canadians with hereditary transthyretin-mediated amyloidosis with polyneuropathy – a ...
Posted by Michael Wonder on 02 Oct 2018
Health Canada approves Tresiba for children with Type 1 diabetes
1 October 2018 - Rates of Type 1 diabetes among children and youth on the rise globally. ...
Posted by Michael Wonder on 26 Sep 2018
AbbVie receives approval from Health Canada for the combination of Venclexta with rituximab as a treatment for patients with chronic lymphocytic leukaemia
25 September 2018 - In the MURANO Phase 3 clinical trial, the Venclexta (venetoclax) plus rituximab combination showed a significant improvement ...
Posted by Michael Wonder on 21 Sep 2018
Health Canada has authorised Takhyzro (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema attacks
20 September 2018 - New treatment option for HAE receives first international marketing authorization outside of the U.S. ...
Posted by Michael Wonder on 20 Sep 2018
Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of adults with previously treated advanced renal cell carcinoma
19 September 2018 - Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus ...
Posted by Michael Wonder on 19 Sep 2018
Sunovion announces Health Canada approval of Aptiom (eslicarbazepine acetate) as adjunctive therapy for the treatment of partial-onset seizures in adolescents and children above six years of age
19 September 2018 - Sunovion Pharmaceuticals today announced that Health Canada approved the supplemental new drug submission to expand the ...
Posted by Michael Wonder on 15 Sep 2018
Herceptin (trastuzumab) subcutaneous formulation approved in Canada for the treatment of HER2-positive breast cancer
13 September 2018 - Subcutaneous formulation takes two to five minutes to administer, rather than up to 90 minutes with the ...
Posted by Michael Wonder on 12 Sep 2018
Health Canada approves Merck's Stromectol (ivermectin) for the treatment of intestinal strongyloidiasis and onchocerciasis
11 September 2018 - The product's availability is expected in November 2018. ...
Posted by Michael Wonder on 11 Sep 2018
Cipher Pharmaceuticals receives Health Canada approval of Xydalba (dalbavancin hydrochloride)
10 September 2018 - Cipher Pharmaceuticals today announced it received Health Canada approval of Xydalba (dalbavancin hydrochloride), the first and ...
Posted by Michael Wonder on 07 Sep 2018
Monoferric (iron isomaltoside 1000 for injection) receives marketing approval from Health Canada
6 September 2018 - Pharmacosmos is delighted to announce that marketing approval has been granted for Monoferric (global brand name Monofer) ...
Posted by Michael Wonder on 07 Sep 2018
Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
6 September 2018 - Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory ...
Posted by Michael Wonder on 05 Sep 2018
Baxter announces Health Canada approval of Olimel 7.6% high protein parenteral nutrition formulations
4 September 2018 - Highest protein and lowest glucose formulation among parenteral nutrition products (with or without electrolytes) available in a ...
Posted by Michael Wonder on 05 Sep 2018
Health Canada approves Perjeta (pertuzumab) for the treatment of HER2 positive early breast cancer after surgery
4 September 2018 - New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning ...
Posted by Michael Wonder on 21 Aug 2018
Canada approves Daewoong Pharmaceutical’s BTX Nabota
20 August 2018 - South Korea’s Daewoong Pharmaceutical said Monday that Health Canada had granted marketing approval for its type ...
Posted by Michael Wonder on 20 Aug 2018
Evolus granted approval of DWP-450 by Health Canada
17 August 2018 - Evolus today announced that Health Canada has granted approval of DWP-450 (prabotulinumtoxinA) for the temporary improvement ...